Accéder au contenu
Merck
Toutes les photos(1)

Documents

1448956

USP

Mycophenolate mofetil

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

(4E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester, RS 61443, TM-MMF

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C23H31NO7
Numéro CAS:
128794-94-5
Poids moléculaire :
433.49
Numéro MDL:
MFCD00867568
Code UNSPSC :
41116107
ID de substance PubChem :
329750505
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

mycophenolate

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

15-25°C

Chaîne SMILES 

COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN3CCOCC3

InChI

1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+

Clé InChI

RTGDFNSFWBGLEC-SYZQJQIISA-N

Informations sur le gène

human ... IMPDH1(3614) , IMPDH2(3615)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Actions biochimiques/physiologiques

Mycophenolate mofetil is a prodrug of mycophenolic acid (Cat. # M5255) that is cleaved by nonspecific esterases in vivo to produce the parent compound. Mycophenolic acid blocks inosine monophosphate dehydrogenase and is a potent immunosuppresive agent.

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0000489

Mycophenolate mofetil, European Pharmacopoeia (EP) Reference Standard

Y0000519

Mycophenolate mofetil for peak identification, European Pharmacopoeia (EP) Reference Standard

1448967

Mycophenolate Mofetil Related Compound A, United States Pharmacopeia (USP) Reference Standard

1448978

Mycophenolate Mofetil Related Compound B, United States Pharmacopeia (USP) Reference Standard

1448989

Mycophenolate sodium, United States Pharmacopeia (USP) Reference Standard

Y0002200

Mycophenolate for system suitability, European Pharmacopoeia (EP) Reference Standard

PHR2776

Mycophenolate Mofetil Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material, pkg of 100 mg

PHR3211

Mycophenolate Sodium, pharmaceutical secondary standard, certified reference material

Pictogrammes

Health hazardExclamation markEnvironment
GHS08,GHS07,GHS09

Mention d'avertissement

Danger

Mentions de danger

H302,H360D,H372,H410

Classification des risques

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 1B - STOT RE 1

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 5

1 of 5

Mycophenolic acid solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

M-106

Mycophenolic acid solution

Teriflunomide ≥98% (HPLC)

Sigma-Aldrich

SML0936

Teriflunomide

Dimethyl fumarate certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

Supelco

50744

Dimethyl fumarate

Tacrolimus United States Pharmacopeia (USP) Reference Standard

USP

1642802

Tacrolimus

Rapamycin VETRANAL®, analytical standard

Supelco

37094

Rapamycin

A D Goralczyk et al.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 12(10), 2601-2607 (2012-07-21)
Liver transplant recipients are at high risk of developing acute and chronic renal failure. Moreover, introduction of the model for end-stage liver disease (MELD) score for primary allocation of liver grafts favors patients with pretransplant kidney dysfunction, which in turn
P Satwani et al.
Leukemia, 29(2), 448-455 (2014-06-19)
The outcome of children, adolescents and young adults (CAYA) with poor-risk recurrent/refractory lymphoma is dismal (⩽30%). To overcome this poor prognosis, we designed an approach to maximize an allogeneic graft vs lymphoma effect in the setting of low disease burden.
K Budde et al.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 14(12), 2796-2806 (2014-10-04)
This Phase III randomized trial examined efficacy and safety of a novel once-daily extended-release tacrolimus formulation (LCP-Tacro [LCPT]) versus twice-daily tacrolimus in de novo kidney transplantation. Primary efficacy end point was proportion of patients with treatment failure (death, graft failure
John Seal et al.
Transplantation, 99(3), 623-628 (2014-08-26)
There is a paucity of contemporary data describing the results of pancreas retransplantation (PRT). As a measure of utility, we wished to determine whether PRT could produce equivalent short-term and long-term recipient outcomes to primary pancreas after kidney (PAK) transplantation.
Andrew Bentall et al.
Transplantation, 98(10), 1089-1096 (2014-06-10)
ABO-incompatible kidney transplantations (ABOiKTxs) seem to have better long-term outcomes than positive crossmatch kidney transplantations (+XMKTxs). This study aimed to assess the differences in chronic injury on histologic findings on 1- and 5-year surveillance biopsies and the clinical outcomes in
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique